Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP

• Status: Unknown status
• Trial end date: 2015-12-01

Summary

The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented. The contribution of prednisolone to CINV control in the R-CHOP regimen is also unclear.

This study aims to evaluate the overall effectiveness of antiemetic control using a standardised 5HT3 (5-Hydroxytryptamine 3) antagonist-containing regimen (e.g. ondansetron) in a heterogeneous group of patients receiving R-CHOP chemotherapy (Rituximab Doxorubicin Vincristine Cyclophosphamide Prednisolone).

• Phase: N/A

Details

• Lead Sponsor: Australasian Leukaemia and Lymphoma Group
• Collaborators: Merck Sharp & Dohme (Australia) Pty Limited; Merck Sharp & Dohme Corp.
• Treatments: Antiemetics; Aprepitant; Cyclophosphamide; Doxorubicin; Emetics; Fosaprepitant; Granisetron; Lorazepam; Methylprednisolone; Methylprednisolone acetate; Methylprednisolone Hemisuccinate; Metoclopramide; Ondansetron; Palonosetron; Prednisolone; Prednisolone acetate; Prednisolone hemisuccinate; Prednisolone phosphate; Prochlorperazine; Tropisetron; Vincristine